Immunic Inc (IMUX) - Total Liabilities
Based on the latest financial reports, Immunic Inc (IMUX) has total liabilities worth $30.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immunic Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Immunic Inc's total liabilities have evolved over time, based on quarterly financial data. See Immunic Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Immunic Inc Competitors by Total Liabilities
The table below lists competitors of Immunic Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acme United Corporation
NYSE MKT:ACU
|
USA | $78.52 Million |
|
INFOM
KLSE:0265
|
Malaysia | RM244.87 Million |
|
Userjoy Technology Co Ltd
TWO:3546
|
Taiwan | NT$909.33 Million |
|
Heungkuk F&M I
KO:000540
|
Korea | ₩12.24 Trillion |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
India | Rs1.79 Billion |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩103.22 Billion |
|
MAX Automation SE
XETRA:MXHN
|
Germany | €155.73 Million |
|
Silver Mountain Resources Inc
V:AGMR
|
Canada | CA$31.60 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Immunic Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IMUX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunic Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunic Inc (2011–2025)
The table below shows the annual total liabilities of Immunic Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.73 Million | +36.93% |
| 2024-12-31 | $22.44 Million | -11.55% |
| 2023-12-31 | $25.37 Million | +80.31% |
| 2022-12-31 | $14.07 Million | +17.39% |
| 2021-12-31 | $11.98 Million | +32.05% |
| 2020-12-31 | $9.08 Million | +19.55% |
| 2019-12-31 | $7.59 Million | +197.61% |
| 2018-12-31 | $2.55 Million | -75.33% |
| 2017-12-31 | $10.34 Million | +85.30% |
| 2016-12-31 | $5.58 Million | -17.41% |
| 2015-12-31 | $6.76 Million | -35.77% |
| 2014-12-31 | $10.52 Million | +103.58% |
| 2013-12-31 | $5.17 Million | -81.52% |
| 2012-12-31 | $27.96 Million | -50.80% |
| 2011-12-31 | $56.84 Million | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more